Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a hurting fact-finding and evolvement Agreement (CRADA) with the United States Naval Health sounding Center for preclinical studies evaluating Adamas' triple union antiviral drug (TCAD) therapy for effervescence A, including novel affliction A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral unity drug, to be boss* adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

More: - Continued here